Cargando…
Efficacy and Safety of Yukgunja-Tang for Patients with Cancer-related Anorexia: A Randomized, Controlled Trial, Pilot Study
OBJECTIVE: The purpose of this study is both to estimate the efficacy and the safety of Yukgunja-tang (YGJT) and to establish evidence for the use of herbal medicines in the management of patients with cancer-related anorexia. METHODS: We enrolled 40 patients with cancer-related anorexia. The enroll...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371029/ https://www.ncbi.nlm.nih.gov/pubmed/34032151 http://dx.doi.org/10.1177/15347354211019107 |
_version_ | 1783739557353619456 |
---|---|
author | Ko, Myung-Hyun Song, Si-Yeon Ha, Su-Jeong Lee, Jee Young Yoon, Seong Woo Park, Ji-Hye Park, So-Jung Yoo, Hwa-Seung |
author_facet | Ko, Myung-Hyun Song, Si-Yeon Ha, Su-Jeong Lee, Jee Young Yoon, Seong Woo Park, Ji-Hye Park, So-Jung Yoo, Hwa-Seung |
author_sort | Ko, Myung-Hyun |
collection | PubMed |
description | OBJECTIVE: The purpose of this study is both to estimate the efficacy and the safety of Yukgunja-tang (YGJT) and to establish evidence for the use of herbal medicines in the management of patients with cancer-related anorexia. METHODS: We enrolled 40 patients with cancer-related anorexia. The enrolled participants were randomly allocated to 2 groups: the control group (n = 20), which received nutrition counseling, and the treatment group (n = 20), which received nutrition counseling and was administered YGJT at twice a day for 4 weeks (a total of 56 times @ 3.0 g each time). The primary outcome of this study was the score on the anorexia/cachexia subscale (ACS) of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT). The secondary outcomes were the FAACT score with the ACS score excluded, the score on the Visual Analog Scale (VAS) for appetite, and the results on laboratory tests regarding appetite, such as leptin, tumor necrosis factors (TNF-α), interleukin-6 (IL-6), and ghrelin. All variables related to the safety assessment, such as vital signs, electrocardiography results, laboratory test results (complete blood cell count, chemistry, urine test), and adverse events, were documented on the case report form (CRF) at every visit. RESULT: The difference in the primary outcome, that is, the score on the anorexia/cachexia subscale (ACS) of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT), between the control and the treatment groups was statistically significant (P = .023) as was the difference in the FAACT scores with the ACS score excluded, a secondary outcome, between the 2 groups; however, no statistically significant differences were noted in the scores on the VAS or the levels of leptin, TNF-α, IL-6, and ghrelin. In addition, no significant differences in the numbers and the types of adverse events or in the results on the laboratory tests between the control and the treatment groups were recorded. CONCLUSION: These results obtained in this research confirmed the efficacy and the safety of using YGJT as a herb-medicine treatment option for patients with cancer-related anorexia. |
format | Online Article Text |
id | pubmed-8371029 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-83710292021-08-19 Efficacy and Safety of Yukgunja-Tang for Patients with Cancer-related Anorexia: A Randomized, Controlled Trial, Pilot Study Ko, Myung-Hyun Song, Si-Yeon Ha, Su-Jeong Lee, Jee Young Yoon, Seong Woo Park, Ji-Hye Park, So-Jung Yoo, Hwa-Seung Integr Cancer Ther Research Article OBJECTIVE: The purpose of this study is both to estimate the efficacy and the safety of Yukgunja-tang (YGJT) and to establish evidence for the use of herbal medicines in the management of patients with cancer-related anorexia. METHODS: We enrolled 40 patients with cancer-related anorexia. The enrolled participants were randomly allocated to 2 groups: the control group (n = 20), which received nutrition counseling, and the treatment group (n = 20), which received nutrition counseling and was administered YGJT at twice a day for 4 weeks (a total of 56 times @ 3.0 g each time). The primary outcome of this study was the score on the anorexia/cachexia subscale (ACS) of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT). The secondary outcomes were the FAACT score with the ACS score excluded, the score on the Visual Analog Scale (VAS) for appetite, and the results on laboratory tests regarding appetite, such as leptin, tumor necrosis factors (TNF-α), interleukin-6 (IL-6), and ghrelin. All variables related to the safety assessment, such as vital signs, electrocardiography results, laboratory test results (complete blood cell count, chemistry, urine test), and adverse events, were documented on the case report form (CRF) at every visit. RESULT: The difference in the primary outcome, that is, the score on the anorexia/cachexia subscale (ACS) of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT), between the control and the treatment groups was statistically significant (P = .023) as was the difference in the FAACT scores with the ACS score excluded, a secondary outcome, between the 2 groups; however, no statistically significant differences were noted in the scores on the VAS or the levels of leptin, TNF-α, IL-6, and ghrelin. In addition, no significant differences in the numbers and the types of adverse events or in the results on the laboratory tests between the control and the treatment groups were recorded. CONCLUSION: These results obtained in this research confirmed the efficacy and the safety of using YGJT as a herb-medicine treatment option for patients with cancer-related anorexia. SAGE Publications 2021-05-25 /pmc/articles/PMC8371029/ /pubmed/34032151 http://dx.doi.org/10.1177/15347354211019107 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Research Article Ko, Myung-Hyun Song, Si-Yeon Ha, Su-Jeong Lee, Jee Young Yoon, Seong Woo Park, Ji-Hye Park, So-Jung Yoo, Hwa-Seung Efficacy and Safety of Yukgunja-Tang for Patients with Cancer-related Anorexia: A Randomized, Controlled Trial, Pilot Study |
title | Efficacy and Safety of Yukgunja-Tang for Patients with Cancer-related
Anorexia: A Randomized, Controlled Trial, Pilot Study |
title_full | Efficacy and Safety of Yukgunja-Tang for Patients with Cancer-related
Anorexia: A Randomized, Controlled Trial, Pilot Study |
title_fullStr | Efficacy and Safety of Yukgunja-Tang for Patients with Cancer-related
Anorexia: A Randomized, Controlled Trial, Pilot Study |
title_full_unstemmed | Efficacy and Safety of Yukgunja-Tang for Patients with Cancer-related
Anorexia: A Randomized, Controlled Trial, Pilot Study |
title_short | Efficacy and Safety of Yukgunja-Tang for Patients with Cancer-related
Anorexia: A Randomized, Controlled Trial, Pilot Study |
title_sort | efficacy and safety of yukgunja-tang for patients with cancer-related
anorexia: a randomized, controlled trial, pilot study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371029/ https://www.ncbi.nlm.nih.gov/pubmed/34032151 http://dx.doi.org/10.1177/15347354211019107 |
work_keys_str_mv | AT komyunghyun efficacyandsafetyofyukgunjatangforpatientswithcancerrelatedanorexiaarandomizedcontrolledtrialpilotstudy AT songsiyeon efficacyandsafetyofyukgunjatangforpatientswithcancerrelatedanorexiaarandomizedcontrolledtrialpilotstudy AT hasujeong efficacyandsafetyofyukgunjatangforpatientswithcancerrelatedanorexiaarandomizedcontrolledtrialpilotstudy AT leejeeyoung efficacyandsafetyofyukgunjatangforpatientswithcancerrelatedanorexiaarandomizedcontrolledtrialpilotstudy AT yoonseongwoo efficacyandsafetyofyukgunjatangforpatientswithcancerrelatedanorexiaarandomizedcontrolledtrialpilotstudy AT parkjihye efficacyandsafetyofyukgunjatangforpatientswithcancerrelatedanorexiaarandomizedcontrolledtrialpilotstudy AT parksojung efficacyandsafetyofyukgunjatangforpatientswithcancerrelatedanorexiaarandomizedcontrolledtrialpilotstudy AT yoohwaseung efficacyandsafetyofyukgunjatangforpatientswithcancerrelatedanorexiaarandomizedcontrolledtrialpilotstudy |